EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

New and emerging options for management of invasive fungal diseases in paediatric patients

Andreas H Groll iD, Katharina Körholz, Malcolm Holterhus iD, Thomas Lehrnbecher

Mycoses · 2024

DOI: 10.1111/myc.13654 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mycoses, 2024. Verfasst von Andreas H Groll und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, Children's University Ho…. Hauptthemen laut MEDLINE: Mycoses, Invasive Fungal Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasive fungal diseases (IFDs) play an important role in the supportive care of paediatric patients with acute leukaemia and those undergoing allogeneic haematopoietic cell transplantation, and they are associated with significantly decreased overall survival rates in affected individuals. Relative to adults, children and adolescents are distinct in terms of host biology, predisposing conditions, presentation and epidemiology of fungal diseases, and in the pharmacology of antifungal agents. The paediatric development of antifungal agents has moved forward in a coordinated manner, and major advances have been made regarding concepts and recommendations for the prevention and treatment of IFDs. However, antifungal therapy is increasingly complex, and a solid knowledge of the available options is needed more than ever for successful management. This narrative review provides a summary of the paediatric development of agents that have been recently approved (anidulafungin, posaconazole) or are in advanced stages of development (isavuconazole). It also reviews the emerging evidence for the efficacy of echinocandins for prophylaxis of invasive aspergillosis, presents new data on alternative dosing regimens of echinocandins and voriconazole, and provides a brief overview of new antifungal agents in clinical development that are expected to be developed for paediatric patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MycosesInvasive Fungal InfectionsAdolescentHumansChildAntifungal AgentsEchinocandinsAnidulafungin

Stichwörter der Autor:innen

antifungal agentschildrenmycosespreventiontreatment

Substanzen

Antifungal AgentsEchinocandinsAnidulafungin

Autor:innen und Institutionen

  • Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, Children's University Hospital Münster, Münster, Germany.
  • Department of Pediatrics, Division of Hematology, Oncology and Hemostaseology, Goethe University Frankfurt, Frankfurt, Germany.

ORCID-Profile: Andreas H Groll, Malcolm Holterhus

Zitieren

APA

Groll, A. H., Körholz, K., Holterhus, M., & Lehrnbecher, T. (2024). New and emerging options for management of invasive fungal diseases in paediatric patients. Mycoses. https://doi.org/10.1111/myc.13654

Vancouver

Groll AH, Körholz K, Holterhus M, Lehrnbecher T. New and emerging options for management of invasive fungal diseases in paediatric patients. Mycoses. 2024. doi:10.1111/myc.13654

BibTeX
@article{Groll2024,
  author = {Groll, Andreas H and Körholz, Katharina and Holterhus, Malcolm and Lehrnbecher, Thomas},
  title = {New and emerging options for management of invasive fungal diseases in paediatric patients},
  journal = {Mycoses},
  year = {2024},
  doi = {10.1111/myc.13654}
}
Kostenlos starten →